tetano
Editor, Senior Moderator
J Med Microbiol. 2018 Jan 10. doi: 10.1099/jmm.0.000676. [Epub ahead of print]
[h=1]Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients.[/h] Mitchell SL[SUP]1[/SUP], Chang YC[SUP]2,[/SUP][SUP]3[/SUP], Feemster K[SUP]2,[/SUP][SUP]3[/SUP], C?rdenas AM[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] Influenza A virus (FluA), influenza B virus (FluB) and respiratory syncytial virus (RSV) illnesses increase hospitalizations during seasonal epidemics.
[h=4]METHODOLOGY:[/h] To determine the utility of the Simplexa FluA/B & RSV Direct Assay (Direct Flu/RSV) and its impact on oseltamivir use, we offered this assay to emergency department (ED) patients with influenza-like illness.
[h=4]RESULTS:[/h] Utilization of the Direct Flu/RSV provided a turnaround time (TAT) of 2 hours. Compared to the flu season prior to implementation of the Direct Flu/RSV, clinicians were more likely to prescribe 5 days of oseltamivir therapy for Direct Flu/RSV-positive patients in comparison to those with a negative test.
[h=4]CONCLUSIONS:[/h] Use of Direct Flu/RSV provides results rapidly, which leads to more appropriate use of oseltamivir. The ease of use of this assay and quick TAT allows for prompt decision-making, which is essential for patient care and effective disease control during the influenza season.
PMID: 29458688 DOI: 10.1099/jmm.0.000676
[h=1]Implementation of a rapid influenza A/B and RSV direct molecular assay improves emergency department oseltamivir use in paediatric patients.[/h] Mitchell SL[SUP]1[/SUP], Chang YC[SUP]2,[/SUP][SUP]3[/SUP], Feemster K[SUP]2,[/SUP][SUP]3[/SUP], C?rdenas AM[SUP]4,[/SUP][SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]PURPOSE:[/h] Influenza A virus (FluA), influenza B virus (FluB) and respiratory syncytial virus (RSV) illnesses increase hospitalizations during seasonal epidemics.
[h=4]METHODOLOGY:[/h] To determine the utility of the Simplexa FluA/B & RSV Direct Assay (Direct Flu/RSV) and its impact on oseltamivir use, we offered this assay to emergency department (ED) patients with influenza-like illness.
[h=4]RESULTS:[/h] Utilization of the Direct Flu/RSV provided a turnaround time (TAT) of 2 hours. Compared to the flu season prior to implementation of the Direct Flu/RSV, clinicians were more likely to prescribe 5 days of oseltamivir therapy for Direct Flu/RSV-positive patients in comparison to those with a negative test.
[h=4]CONCLUSIONS:[/h] Use of Direct Flu/RSV provides results rapidly, which leads to more appropriate use of oseltamivir. The ease of use of this assay and quick TAT allows for prompt decision-making, which is essential for patient care and effective disease control during the influenza season.
PMID: 29458688 DOI: 10.1099/jmm.0.000676